Novartis reported a challenging first quarter for 2026, with profits experiencing a significant downturn primarily due to the intensified impact…
Read More
The Surge in Oncology Innovation Fuels Strategic Investment in HPAPI and ADC Manufacturing Capabilities
The accelerating demand for highly potent active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs) is compelling contract development and manufacturing…
Read More
Pfizer Secures Extended Market Exclusivity for Vyndamax, Delaying Generic Competition Until 2031
Pfizer has successfully negotiated settlements with three drug manufacturers, Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, preventing the immediate launch of…
Read More
Eli Lilly and Profluent Partner to Harness AI for Advanced Recombinase-Based Gene Editing
Eli Lilly and Company, a global leader in pharmaceutical innovation, has announced a significant strategic alliance with Profluent, an artificial…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
Seaport Therapeutics and Hemab Therapeutics Set for Major Public Offerings as Biotech IPO Market Gains Momentum
Seaport Therapeutics and Hemab Therapeutics are poised to join the ranks of publicly traded companies, with both biopharmaceutical firms announcing…
Read More
Merck KGaA and Remepy Forge Groundbreaking Partnership to Pioneer "Hybrid Drugs" for Rare Cancers
In a move that signals a significant shift in pharmaceutical innovation, Merck KGaA has announced a strategic collaboration with Remepy,…
Read More
Home Testing Kits Revolutionize Bowel Cancer Screening, Offering Hope for Earlier Detection and Improved Survival Rates
The advent of accessible home testing kits is significantly transforming the landscape of bowel cancer screening, making it more convenient…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
AI Tools Revolutionize Pharmaceutical Administration, Freeing Up Valuable Human Capital
The pharmaceutical industry is experiencing a significant transformation as artificial intelligence (AI) tools move beyond experimental phases to deliver tangible…
Read More
